Christopher Jewell, Ph.D.

Christopher Jewell, Ph.D.

Former Chief Scientific OfficeratCartesian Therapeutics· In proxies 2023–2025

Pay in FY2025+19% from the year before · Cartesian Therapeutics stock -59.7% the same year

Christopher Jewell, Ph.D. was paid $2.0M in FY2025 (Dec), up 19%. Cartesian Therapeutics stock fell 59.7% that year.

Pay$100 in the stock at the end of FY22 → $21
Pay is from the Summary Compensation Table of each Cartesian Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Cartesian TherapeuticsPublic company · 3 yr
    • Former Chief Scientific Officer2023 – Present · 3 yrStock in role -77%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?